177Lu-PSMA-I&T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer

Condition: Metastatic Castration-resistant Prostate Cancer

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT04188587

Sponsor: Nanjing First Hospital, Nanjing Medical University

Phase: Phase 2


  • Age: minimum 18 Years maximum 90 Years
  • Gender: Male

Exclusion Criteria:

  1. Previous treatment with any of the following within 6 months of randomization: Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation. Previous PSMA-targeted radioligand therapy is not allowed.
  2. Hemoglobin<80g/L;Hemameba<2.5×109/L;Thrombocyte<70g/L
  3. Glomerular filtration rate<50ml/min
  4. Serum creatinine>130umol/L;Total bilirubin>2mg/L;Albumin<30g/L.
  5. International normalized ratio(INR)>1,5
  6. Alanine aminotransferase, aspartate aminotransferase is 5 times larger than normal value

View trial on ClinicalTrials.gov

email news signup